Cell & Gene Therapy (CGT)

CGT modifies or manipulates gene expression to alter cell biology, offering curative potential for diseases beyond the reach of traditional drugs, and is currently the hottest sector in biologics. However, CGT processes face severe challenges: viral vectors are easily inactivated, process recovery rates are low, and downstream purification is highly difficult (e.g., removing empty AAV capsids).

Addressing these unique CGT challenges, Alioth combines product advantages, technical expertise, and regulatory support to deliver complete filtration solutions — from viral vector harvest clarification through purification to concentration — aimed at improving process recovery and robustness, and helping CGT drugs advance from clinical development to commercial-scale manufacturing.